by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Lovelace Biomedical Research Institute Warning Letter Details

Warning Letter

Lovelace Biomedical Research Institute

2425 Ridgecrest Drive SE Albuquerque , NM 87108 United States

Issue DateOctober 06, 2026

FEI NumberN/A

Violations1

CountryUnited States

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

Lovelace Biomedical Research Institute FDA Warning Letter, October 6, 2026